Ovarian cancer presents at a late clinical stage in more than 80% of patients It is associated with a 5-year survival rate of 35% Thus, there is a great need to develop more promising agents for the treatment and prognosis of ovarian cancer. TGFbeta is known to be a tumor suppressor, and intracellular components that mediate its biological effects can also function in this manner. Further, resistance to the growth inhibitory effects of TGFbeta occurs in approximately 75% of ovarian cancer cases, especially with recurrent disease. We have identified a novel TGFbeta signaling component, termed km23, which is also a light chain of the motor protein dynein. This cytoplasmic component interacts with the TGFbeta receptors and is phosphorylated upon TGFbeta receptor activation. Further, expression of km23 mediates specific TGFbeta responses, including growth inhibition of epithelial cells Moreover, we have identified alterations in km23 in 4 out of 11 epithelial ovarian cancers from human patients, and in 33% of human ovarian cancer cell (HOCC) lines. Since km23 appears to be a TGFbeta signaling component that is altered in human ovarian cancer, we hypothesize that expression of the """"""""tumor-like"""""""" km23 alterations in TGFbeta-sensitive HOCCs will suppress the ability of TGFbeta to inhibit the growth of these cells, and produce a more malignant phenotype The overall goal of this proposal is to determine whether the km23 alterations identified in ovarian cancer patients will result in altered growth control by TGFbeta, a more transformed phenotype in vitro, and increased tumorigenicities in vivo. We will also extend our analyses of human cancer tissues to determine the frequency and stage of disease at which the changes occur, as well as the frequency in the normal population. Additional studies will identify the kinase that phosphorylates km23, as well as the precise km23 phosphorylation sites. Finally, we will identify the exact domains of interaction between km23 and the intermediate chain of the motor protein dynein, and determine how alterations in km23 affect this interaction. We hypothesize that the latter two types of studies will assist in the development of screens by which to identify novel agents for the treatment of ovarian cancer ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA100239-05
Application #
7218712
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Blair, Donald G
Project Start
2003-04-01
Project End
2010-03-31
Budget Start
2007-04-01
Budget End
2010-03-31
Support Year
5
Fiscal Year
2007
Total Cost
$315,822
Indirect Cost
Name
Pennsylvania State University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
129348186
City
Hershey
State
PA
Country
United States
Zip Code
17033
Pandey, Manoj K; Liu, Guangming; Cooper, Timothy K et al. (2012) Knockdown of c-Fos suppresses the growth of human colon carcinoma cells in athymic mice. Int J Cancer 130:213-22
Jin, Qunyan; Ding, Wei; Mulder, Kathleen M (2012) The TGF? receptor-interacting protein km23-1/DYNLRB1 plays an adaptor role in TGF?1 autoinduction via its association with Ras. J Biol Chem 287:26453-63
Jin, Qunyan; Gao, Guofeng; Mulder, Kathleen M (2012) Requirement of a dynein light chain in transforming growth factor ? signaling in zebrafish ovarian follicle cells. Mol Cell Endocrinol 348:233-40
Pulipati, Nageswara R; Jin, Qunyan; Liu, Xin et al. (2011) Overexpression of the dynein light chain km23-1 in human ovarian carcinoma cells inhibits tumor formation in vivo and causes mitotic delay at prometaphase/metaphase. Int J Cancer 129:553-64
Jin, Qunyan; Gao, Guofeng; Mulder, Kathleen M (2009) Requirement of a dynein light chain in TGFbeta/Smad3 signaling. J Cell Physiol 221:707-15
Jin, Qunyan; Ding, Wei; Mulder, Kathleen M (2007) Requirement for the dynein light chain km23-1 in a Smad2-dependent transforming growth factor-beta signaling pathway. J Biol Chem 282:19122-32
Liu, Guangming; Ding, Wei; Neiman, Jill et al. (2006) Requirement of Smad3 and CREB-1 in mediating transforming growth factor-beta (TGF beta) induction of TGF beta 3 secretion. J Biol Chem 281:29479-90
Liu, Guangming; Ding, Wei; Liu, Xin et al. (2006) c-Fos is required for TGFbeta1 production and the associated paracrine migratory effects of human colon carcinoma cells. Mol Carcinog 45:582-93
Jin, Qunyan; Ding, Wei; Staub, Cory M et al. (2005) Requirement of km23 for TGFbeta-mediated growth inhibition and induction of fibronectin expression. Cell Signal 17:1363-72
Ilangovan, Udayar; Ding, Wei; Zhong, Yan et al. (2005) Structure and dynamics of the homodimeric dynein light chain km23. J Mol Biol 352:338-54

Showing the most recent 10 out of 11 publications